Literature DB >> 16247465

AML1 deletion in adult mice causes splenomegaly and lymphomas.

G Putz1, A Rosner, I Nuesslein, N Schmitz, F Buchholz.   

Abstract

AML1 (RUNX1) encodes a DNA-binding subunit of the CBF transcription factor family and is required for the establishment of definitive hematopoiesis. AML1 is one of the most frequently mutated genes associated with human acute leukemia, suggesting that genetic alterations of the gene contribute to leukemogenesis. Here, we report the analysis of mice carrying conditional AML1 knockout alleles that were inactivated using the Cre/loxP system. AML1 was deleted in adult mice by inducing Cre activity to replicate AML1 deletions found in human MDS, familial platelet disorder and rare de novo human AML. At a latency of 2 months after induction, the thymus was reduced in size and frequently populated by immature double negative thymocytes, indicating defective T-lymphocyte maturation, resulting in lymphatic diseases with 50% penetrance, including atypical hyperplasia and thymic lymphoma. Metastatic lymphomas to the liver and the meninges were observed. Mice also developed splenomegaly with an expansion of the myeloid compartment. Increased Howell-Jolly body counts indicated splenic hypofunction. Thrombocytopenia occurred due to immaturity of mini-megakaryocytes in the bone marrow. Together with mild lymphocytopenia in the peripheral blood and increased fractions of immature cells in the bone marrow, AML1 deficient mice display features of a myelodysplastic syndrome, suggesting a preleukemic state.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16247465     DOI: 10.1038/sj.onc.1209136

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

1.  Thrombocytopenia in mice lacking the carboxy-terminal regulatory domain of the Ets transcription factor Fli1.

Authors:  Omar Moussa; Amanda C LaRue; Romeo S Abangan; Christopher R Williams; Xian K Zhang; Masahiro Masuya; Yong Z Gong; Demetri D Spyropoulos; Makio Ogawa; Gary Gilkeson; Dennis K Watson
Journal:  Mol Cell Biol       Date:  2010-09-07       Impact factor: 4.272

Review 2.  The RUNX complex: reaching beyond haematopoiesis into immunity.

Authors:  Dominic Chih-Cheng Voon; Yit Teng Hor; Yoshiaki Ito
Journal:  Immunology       Date:  2015-10-25       Impact factor: 7.397

3.  T-lymphoid, megakaryocyte, and granulocyte development are sensitive to decreases in CBFbeta dosage.

Authors:  Laleh Talebian; Zhe Li; Yalin Guo; Justin Gaudet; Maren E Speck; Daisuke Sugiyama; Prabhjot Kaur; Warren S Pear; Ivan Maillard; Nancy A Speck
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

4.  A regulatory interplay between miR-27a and Runx1 during megakaryopoiesis.

Authors:  Oren Ben-Ami; Niv Pencovich; Joseph Lotem; Ditsa Levanon; Yoram Groner
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-29       Impact factor: 11.205

Review 5.  Normal and malignant megakaryopoiesis.

Authors:  Qiang Wen; Benjamin Goldenson; John D Crispino
Journal:  Expert Rev Mol Med       Date:  2011-10-21       Impact factor: 5.600

6.  Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma.

Authors:  Lei Chen; Cong-Fa Huang; Yi-Cun Li; Wei-Wei Deng; Liang Mao; Lei Wu; Wen-Feng Zhang; Lu Zhang; Zhi-Jun Sun
Journal:  Cell Mol Life Sci       Date:  2017-11-28       Impact factor: 9.261

7.  A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.

Authors:  Boet van Riel; Tibor Pakozdi; Rutger Brouwer; Rui Monteiro; Kapil Tuladhar; Vedran Franke; Jan Christian Bryne; Ruud Jorna; Erik-Jan Rijkers; Wilfred van Ijcken; Charlotte Andrieu-Soler; Jeroen Demmers; Roger Patient; Eric Soler; Boris Lenhard; Frank Grosveld
Journal:  Mol Cell Biol       Date:  2012-07-16       Impact factor: 4.272

8.  Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis.

Authors:  Bindya Jacob; Motomi Osato; Namiko Yamashita; Chelsia Qiuxia Wang; Ichiro Taniuchi; Dan R Littman; Norio Asou; Yoshiaki Ito
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

Review 9.  A role for RUNX1 in hematopoiesis and myeloid leukemia.

Authors:  Motoshi Ichikawa; Akihide Yoshimi; Masahiro Nakagawa; Nahoko Nishimoto; Naoko Watanabe-Okochi; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

10.  PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis.

Authors:  Hee-Jun Wee; Dominic Chih-Cheng Voon; Suk-Chul Bae; Yoshiaki Ito
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.